Porphyria cutanea tarda

WikiDoc Resources for Porphyria cutanea tarda
Articles
Most recent articles on Porphyria cutanea tarda Most cited articles on Porphyria cutanea tarda Review articles on Porphyria cutanea tarda Articles on Porphyria cutanea tarda in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Porphyria cutanea tarda Images of Porphyria cutanea tarda Photos of Porphyria cutanea tarda Podcasts & MP3s on Porphyria cutanea tarda Videos on Porphyria cutanea tarda
Evidence Based Medicine
Cochrane Collaboration on Porphyria cutanea tarda Bandolier on Porphyria cutanea tarda TRIP on Porphyria cutanea tarda
Clinical Trials
Ongoing Trials on Porphyria cutanea tarda at Clinical Trials.gov Trial results on Porphyria cutanea tarda Clinical Trials on Porphyria cutanea tarda at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Porphyria cutanea tarda NICE Guidance on Porphyria cutanea tarda NHS PRODIGY Guidance FDA on Porphyria cutanea tarda CDC on Porphyria cutanea tarda
Books
Books on Porphyria cutanea tarda
News
Porphyria cutanea tarda in the news Be alerted to news on Porphyria cutanea tarda News trends on Porphyria cutanea tarda
Commentary
Blogs on Porphyria cutanea tarda
Definitions
Definitions of Porphyria cutanea tarda
Patient Resources / Community
Patient resources on Porphyria cutanea tarda Discussion groups on Porphyria cutanea tarda Patient Handouts on Porphyria cutanea tarda Directions to Hospitals Treating Porphyria cutanea tarda Risk calculators and risk factors for Porphyria cutanea tarda
Healthcare Provider Resources
Symptoms of Porphyria cutanea tarda Causes & Risk Factors for Porphyria cutanea tarda Diagnostic studies for Porphyria cutanea tarda Treatment of Porphyria cutanea tarda
Continuing Medical Education (CME)
CME Programs on Porphyria cutanea tarda
International
Porphyria cutanea tarda en Espanol Porphyria cutanea tarda en Francais
Business
Porphyria cutanea tarda in the Marketplace Patents on Porphyria cutanea tarda
Experimental / Informatics
List of terms related to Porphyria cutanea tarda

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]

Overview

Porphyria cutanea tarda (PCT) is the most common subtype of porphyria. The disorder results from low levels of the enzyme responsible for the fifth step in heme production. Heme is a vital molecule for all of the body's organs. It is a component of hemoglobin, the molecule that carries oxygen in the blood.

Presentation

When signs and symptoms occur, they usually begin in adulthood and result from the skin becoming overly sensitive to sunlight. Areas of skin exposed to the sun develop severe blistering, scarring, changes in pigmentation, and increased hair growth. Exposed skin becomes fragile and is easily damaged. People with porphyria cutanea tarda also have increased iron levels in the liver. They face a higher risk of developing abnormal liver function and liver cancer.

Causes

• In the acquired form, the signs and symptoms of this condition are triggered by non genetic factors such as alcohol abuse, excess iron, certain hormones, and viral infections. However, in the inherited form of the disease, which affects up to 20% of PCT patients, the condition arises from a mutation in the uroporphyrinogen decarboxylase gene, although environmental and chemical factors may trigger or exacerbate symptoms.
• Drug side effect: Tolbutamide

Diagnosis

Physical Examination

Skin

Extremities

• 

  Porphyria cutanea tarda. Adapted from Dermatology Atlas.

• 

  Porphyria cutanea tarda. Adapted from Dermatology Atlas.

• 

  Porphyria cutanea tarda. Adapted from Dermatology Atlas.

• 

  Porphyria cutanea tarda. Adapted from Dermatology Atlas.

• 

  Porphyria cutanea tarda. Adapted from Dermatology Atlas.

• 

  Porphyria cutanea tarda. Adapted from Dermatology Atlas.

• 

  Porphyria cutanea tarda. Adapted from Dermatology Atlas.

• 

  Porphyria cutanea tarda. Adapted from Dermatology Atlas.

• 

  Porphyria cutanea tarda. Adapted from Dermatology Atlas.

• 

  Porphyria cutanea tarda. Adapted from Dermatology Atlas.

• 

  Porphyria cutanea tarda. Adapted from Dermatology Atlas.

• 

  Porphyria cutanea tarda. Adapted from Dermatology Atlas.

• 

  Porphyria cutanea tarda. Adapted from Dermatology Atlas.

Face

• 

  Porphyria cutanea tarda. Adapted from Dermatology Atlas.

Epidemiology

This type of porphyria occurs in an estimated 1 in 25,000 people, including both inherited and sporadic (noninherited) cases. An estimated 80 % of porphyria cutanea tarda cases are sporadic. The exact frequency is not clear because many people with the condition never experience symptoms.

Genetics

Inherited mutations in the UROD gene cause about 20 % of cases (the other 80 % of cases do not have mutations in UROD, and are classified as sporadic). UROD makes an enzyme called uroporphyrinogen III decarboxylase, which is critical to the chemical process that leads to heme production. The activity of this enzyme is usually reduced by 50 % in all tissues in people with the inherited form of the condition.

Nongenetic factors such as alcohol abuse, excess iron, and others listed above can increase the demand for heme and the enzymes required to make heme. The combination of this increased demand and reduced activity of uroporphyrinogen decarboxylase disrupts heme production and allows byproducts of the process to accumulate in the body, triggering the signs and symptoms of porphyria cutanea tarda.

The HFE gene makes a protein that helps cells regulate the absorption of iron from the digestive tract and into the cells of the body. Certain mutations in the HFE gene cause hemochromatosis (an iron overload disorder). People who have these mutations are also at an increased risk of developing porphyria cutanea tarda.

In the 20% of cases where porphyria cutanea tarda is inherited, it is inherited in an autosomal dominant pattern, which means one copy of the altered gene is sufficient to decrease enzyme activity and cause the signs and symptoms of the disorder.

20% of cases of porphyria cutanea tarda are inherited in an autosomal dominant pattern.

Diagnosis

Physical Examination

Skin

• DiseaseName. Adapted from Dermatology Atlas.[2]

  DiseaseName. Adapted from Dermatology Atlas.

• File:DiseaseName

Treatment

Chloroquine and venesection can be part of a management strategy.

Cultural references

Porphyria Cutanea Tarda is also the name of a song by the punk band AFI on their album Black Sails in the Sunset.

Additional Resources

• Kauppinen R (2005). "Porphyrias". Lancet. 365 (9455): 241–52. PMID 15652607.
• Lecha M, Herrero C, Ozalla D (2003). "Diagnosis and treatment of the hepatic porphyrias". Dermatol Ther. 16 (1): 65–72. PMID 12919129.CS1 maint: Multiple names: authors list (link)
• Nordmann Y, Puy H (2002). "Human hereditary hepatic porphyrias". Clin Chim Acta. 325 (1–2): 17–37. PMID 12367763.
• Sassa S (2002). "The porphyrias". Photodermatol Photoimmunol Photomed. 18 (2): 56–67. PMID 12147038.
• "Porphyria Cutanea Tarda" Porphyria South Africa, University of Cape Town/Groote Schurr Hospital

Template:Vesiculobullous disease Template:Endocrine, nutritional and metabolic pathology Template:SIB

Template:WikiDoc Sources